CISH and neoplasm: Genetic engineering of TILs via CRISPR/Cas9 to delete inhibitory regulators like CISH or SOCS1 has shown promise in preclinical models, leading to enhanced tumor infiltration, polyfunctionality, and complete tumor regression (160, 166).